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Introduction
Focal adhesions are sites of matrix engagement with cell sur-
face integrin clusters that are linked to the actin cytoskeleton at 
stress fi  ber termini through interactions with multiple intracel-
lular proteins, such as talin, vinculin, and paxillin (Webb et al., 
2002; Carragher and Frame, 2004). The signaling and molecu-
lar mechanisms leading to focal adhesion assembly are well 
characterized and involve multiple Rho family GTPases, actin 
binding proteins, and integrin-matrix binding (Webb et al., 
2002). In contrast, relatively little is known about the mecha-
nisms involved in adhesion disassembly, but the involvement of 
Rho–Rho kinase (ROCK) signaling, calpains, and microtubules 
have been proposed (Carragher and Frame, 2004; Ezratty et al., 
2005). In particular, Rho–ROCK promotes focal adhesion dis-
assembly at the cell rear, and inhibition of this pathway pro-
duces a striking contractile and/or tail-retraction defect that is 
associated with decreased myosin light chain (MLC) 2 phos-
phorylation in various cell types (Itoh et al., 1999; Somlyo 
et al., 2000; Alblas et al., 2001; Worthylake et al., 2001; Riento 
and Ridley, 2003; Wilkinson et al., 2005).
ROCK-based contractility is not only involved in the dis-
assembly of cell–matrix adhesions during tail retraction but can 
also disrupt the stability of cell–cell adhesions associated with 
adherens junctions (Sahai and Marshall, 2002). Adherens junc-
tions occur at sites of cell–cell contact in organized epithelial 
cell monolayers and are formed via the homotypic interaction 
between E-cadherin on adjacent cells. The cytoplasmic tail of 
E-cadherin is linked to the actin cytoskeleton through interac-
tions with catenin proteins (α, β, and p120) and actin binding 
proteins (vinculin). Adherens junctions can be regulated by 
translational events but are also subject to direct control by 
posttranslational cellular mechanisms, including their disas-
sembly by the actin cytoskeleton and endocytosis (D’Souza-
Schorey, 2005).
Endocytic dynamics have been shown to coordinate sev-
eral key intracellular signaling events (Kermorgant et al., 2004; 
Polo et al., 2004; Le Roy and Wrana, 2005). In this study, we 
investigated whether endosomal signaling could represent an 
integral part of the deadhesion process, both in rear cell retrac-
tion and adherens junction breakdown. In particular, we have 
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investigated the role of the endocytic receptor Endo180 in these 
events. Endo180 (also known as CD280; uPARAP) is a 180-kD 
type I transmembrane receptor comprised of an N-terminal 
  cysteine-rich domain followed by a fi  bronectin type II (FNII), 
8 C-type lectin-like domains, a single transmembrane domain, 
and a short cytoplasmic domain (East and Isacke, 2002; 
  Behrendt, 2004). Within this cytoplasmic domain, a critical 
 dihydrophobic  Leu
1468/Val
1469 motif mediates the constitutive 
recruitment of Endo180 into clathrin-coated pits on the cell sur-
face, which is followed by rapid internalization into intracellu-
lar endosomes and effi  cient recycling back to the cell surface 
(Isacke et al., 1990; Howard and Isacke, 2002). This traffi  cking 
of Endo180 is essential for its function as a collagen internaliza-
tion receptor in which collagen bound to Endo180 is rapidly 
taken up into the endosomes and then dissociated from the re-
ceptor for delivery to, and degradation in, lysosomal compart-
ments (Engelholm et al., 2003; Wienke et al., 2003; Kjoller et al., 
2004; Curino et al., 2005). In addition to its role in ligand inter-
nalization, a promigratory function for Endo180 has also been 
demonstrated. Cells derived from mice with a targeted deletion 
in Endo180 and in which Endo180 expression is knocked down 
by siRNA oligonucleotides both display a reduced migratory 
capacity. Conversely, ectopic expression of Endo180 in Endo180-
negative cell lines results in the acquisition of a polarized phe-
notype and enhanced cell migration (East et al., 2003; Engelholm 
et al., 2003; Sturge et al., 2003). Here, we have further investi-
gated the promigratory function of this receptor and provide a 
mechanism by which intracellular Endo180 can spatially regu-
late cell contractility and adhesion dynamics.
Results
Rear cell deadhesion and cell contractility 
are regulated by the endocytic 
receptor Endo180
The potential involvement of endosomes in the spatial activation 
of ROCK during rear cell deadhesion was investigated by com-
paring the effects of ROCK inhibition with the down-regulation 
of constitutively recycling endocytic receptors. Treatment of 
MG63 osteosarcoma cells with ROCK inhibitor produced a tail-
retraction defect that was associated with a decrease in MLC2 
phosphorylation (Fig. 1, a and b; and Fig. S1 a, available 
at http://www.jcb.org/cgi/content/full/jcb.200602125/DC1), 
consistent with its effects in other cell types (Itoh et al., 1999; 
Somlyo et al., 2000; Alblas et al., 2001; Worthylake et al., 2001; 
Riento and Ridley, 2003; Wilkinson et al., 2005). Three endo-
cytic receptors, Endo180, transferrin receptor, and low-density 
lipoprotein (LDL) receptor, were targeted with siRNA oligonu-
cleotides (Fig. S1 b). These receptors were chosen as Endo180 
drives cell migration through an endocytosis-dependent mecha-
nism (Sturge et al., 2003) and transferrin receptor enhances cell 
migration on a transferrin substrate (Bretscher, 1992). Because 
the LDL receptor (LDLR) has no reported role in cell migration, 
it was included as a negative control. Endo180 siRNA treatment 
Figure 1.  Endo180 is required for contractile 
signals and rear cell deadhesion. (a–c) MG63 
cells were plated onto uncoated glass cover-
slips or tissue culture plastic and treated with 
0.3 μM ROCK inhibitor for 16 h or mock 
transfected, transfected with nontargeting 
scram  bled Endo180 siRNA oligonucleotides 
  (control), Endo180 single siRNA oligonucle-
otides (Endo180 siRNA), Endo180 SMART-
Pool siRNA oligonucleotides (Endo180 siRNA 
SP), or siRNA oligonucleotides against trans-
ferrin receptor (TfR), LDLR, or uPAR, and cul-
tured for 72 h. (a) Cells were ﬁ  xed, and the 
actin cytoskeleton was visualized by staining 
with Alexa 488 phalloidin (green). Cell nuclei 
were counterstained with TO-PRO-3 (blue). 
Bar, 50 μm. Images are representative of four 
separate experiments. (b) Cells in panel a 
were scored for tail formation by counting 
>100 cells in each of four separate experi-
ments. Data are mean ± SEM. *, P < 0.0001, 
compared with untreated cells. (c) Cell lysates 
were resolved by SDS-PAGE and immunoblot-
ted to detect diphospho-MLC2 and total MLC2. 
(top) A representative immunoblot of four sepa-
rate experiments. (bottom) MLC2 phosphoryla-
tion levels quantiﬁ   ed by densitometry. Data 
are mean ± SEM. *, P < 0.0001, compared 
with control. n  = 4. (d) MDA-MB-231, HT-
1080, BE, and MG63 cells were plated onto 
tissue culture plastic and treated with control or 
Endo180 siRNA oligonucleotides for 72 h, 
and levels of diphospho-MLC2 and total MLC2 
were detected as described for panel c. Data 
are mean of four separate experiments ± 
SEM. *, P < 0.01, compared with control.ENDO180 SPATIALLY REGULATES CELL CONTRACTILITY • STURGE ET AL. 339
of MG63 cells resulted in a striking elongated phenotype, indic-
ative of a tail-retraction defect, that was indistinguishable from 
that produced by ROCK inhibition (Fig. 1, a and b). This was not 
an off-target effect of Endo180 siRNA, as an identical phenotype 
was observed using alternate oligonucleotides (Fig. 1, a and b; 
and Fig. S1 c). In contrast, no defect in rear cell deadhesion was 
apparent in transferrin receptor or LDLR siRNA–treated cells 
(Fig. 1, a and b). Further, Endo180 was the only endocytic recep-
tor required for MLC2 phosphorylation (Fig. 1 c and Fig. S1 c). 
Defective cellular contractility and/or rear cell retraction result-
ing from the down-regulation of Endo180 was not restricted to 
MG63 osteosarcoma cells but was also confi  rmed in MDA-MB-
231 breast carcinoma, HT-1080 fi  brosarcoma, and BE colon car-
cinoma cells (Fig. 1 d and Fig. S2 a).
Endo180 is a coreceptor for the glycosphosphatidylinositol-
anchored urokinase-type plasminogen activator (uPA)–uPA re-
ceptor (uPAR) complex (Behrendt et al., 2000) and is required 
for the activation of directional signaling pathways during sens-
ing of a uPA gradient by migrating cells (Sturge et al., 2003). 
Because uPA–uPAR has been reported to regulate Rho–ROCK 
signaling and the phosphorylation of MLC2 (Nguyen et al., 
1999; Jo et al., 2002), we considered this to be a potential regu-
latory component in rear cell deadhesion and contractility pro-
moted by Endo180. To address this possibility, uPAR was 
targeted using siRNA oligonucleotides in MG63 and BE cells, 
which express low and high levels of uPAR, respectively (Fig. 
S1 b and Fig. S2 b). As previously reported (Vial et al., 2003), 
treatment with uPAR siRNA was effective at decreasing mem-
brane ruffl  es in BE colon carcinoma cells (unpublished data). 
However, no tail-retraction defect or reduction in MLC2 phos-
phorylation was observed in either MG63 cells (Fig. 1, a–c) or 
BE cells (Fig. S2 c), indicating that uPA–uPAR does not pro-
mote cell contractility associated with rear cell tail retraction and 
is unlikely to have a role in this particular Endo180-mediated 
event during random cell migration.
Endo180 does not require speciﬁ  c 
extracellular matrix components 
to regulate rear cell deadhesion 
and cell contractility
Endo180 is a well-established collagen binding and internaliza-
tion receptor (Engelholm et al., 2003; Wienke et al., 2003; 
Kjoller et al., 2004; Curino et al., 2005). To investigate whether 
these specifi  c functions of Endo180 played a part in rear cell 
deadhesion and contractility, the behavior of cells targeted for 
knock down of Endo180 on both non–collagen- and collagen-
based substrata was investigated. MG63 cells treated with 
Endo180 siRNA oligonucleotides for 72 h formed unretracted 
tails within 4 h of being seeded onto uncoated glass coverslips 
or glass coverslips coated with fi  bronectin, collagen I, or Matri-
gel (of which collagen IV is a major constituent), whereas on 
all substrata no tail-retraction defect was observed in control 
siRNA–treated cells (Fig. 2 a). Further, MG63 cells grown on 
uncoated tissue culture plastic or tissue culture plastic coated 
with fi  bronectin, collagen I, or Matrigel displayed similar de-
creases in MLC2 phosphorylation (Fig. 2 b). These fi  ndings are 
in keeping with a previous report (Sturge et al., 2003) and new 
data presented here (Fig. S3, available at http://www.jcb.org/
cgi/content/full/jcb.200602125/DC1) that Endo180-mediated 
cell migration is not dependent on collagenous extracellular 
matrix substrata.
Rho–ROCK signaling is a downstream 
target of Endo180
To test the hypothesis that Endo180 regulates ROCK activity, 
a series of experiments were undertaken to assess whether 
Endo180 down-regulation could recapitulate the specifi  c cellu-
lar and biochemical events associated with ROCK inhibition. 
First, a comparison using time-lapse microscopy of tail forma-
tion after global ROCK inhibition and Endo180 siRNA treat-
ment revealed a similar sequence of cellular dynamics (Fig. 3 a 
and Videos 1–3, available at http://www.jcb.org/cgi/content/
full/jcb.200602125/DC1). In both cases, cells exhibited a col-
lapsed morphology, an increase in cell body movement (Fig. 
3 b), and impaired translocation. This resulted in the formation 
of multiple and elongated tails, some of which then became pro-
trusive and displayed localized membrane ruffl  es (Videos 1–3). 
In these assays, it was noted that the tail phenotype produced by 
ROCK inhibition was more extensive than that associated with 
Endo180 siRNA treatment. This most likely is a consequence 
of ROCK inhibition at multiple cellular locations, whereas tails 
Figure 2.  Endo180-generated contractile signals and rear cell deadhe-
sion are not dependent on the extracellular matrix. (a) MG63 cells were 
transfected with nontargeting (control) or targeting siRNA oligonucle-
otides against Endo180 for 72 h. Cells were seeded onto uncoated cov-
erslips or coverslips coated with ﬁ  bronectin, collagen type I, or Matrigel 
and allowed to adhere and spread for 4 h before ﬁ  xation. The actin cyto-
skeleton was visualized by staining with Alexa 488 phalloidin (green), 
and cell nuclei were counterstained with TO-PRO-3 (blue). Images shown 
are representative of two separate experiments. Bar, 50 μm. (b) MG63 
cells seeded onto uncoated tissue culture plastic or tissue culture plastic 
coated with ﬁ  bronectin, collagen type I, or Matrigel were transfected with 
nontargeting (control) or targeting siRNA oligonucleotides against 
Endo180 for 72 h. Cell lysates were resolved by SDS-PAGE and immuno-
blotted to detect diphospho-MLC2 and total MLC2. (top) A representative 
immunoblot from a single experiment. (bottom) MLC2 phosphorylation 
levels quantiﬁ  ed by densitometry. Data are mean of two separate experi-
ments ± SEM.JCB • VOLUME 175 • NUMBER 2 • 2006  340
resulting from Endo180 siRNA treatment were generally re-
stricted to the rear of migrating cells and could result from the 
inhibition of spatially regulated ROCK activity. The global inhi-
bition of ROCK also explains the more collapsed phenotype of 
cells treated with ROCK inhibitor that occurs before their for-
mation of multiple tails (Fig. 3 a, t = 0).
Second, the signaling pathways downstream of ROCK 
were investigated. Activation of MLC2 by ROCK occurs through 
both diphosphorylation at threonine 20/serine 19 and a single 
phosphorylation event at serine 19. ROCK also phosphorylates 
LIM kinase (LIMK) 1/2 at threonine 508/505 and myosin phos-
phatase (MYPT) 1 at threonine 696 (Riento and Ridley, 2003; 
Croft et al., 2004). Treatment of MG63 cells with Endo180 
siRNA or ROCK inhibitor not only reduced the diphosphoryla-
tion of MLC2 (Fig. 4 a, Fig. 1 c, and Fig. S1 a) but also reduced 
the monophosphorylation of MLC2 at serine 19 and decreased 
the phosphorylation of both MYPT1 and LIMK1/2 (Fig. 4 a). The 
reduction in phosphorylation attributed to Endo180 siRNA 
treatment was not due to an effect on kinase stability, as the 
levels of serine/threonine kinases involved in the phosphory-
lation of MLC2 remained unchanged (Fig. S4, available at 
http://www.jcb.org/cgi/content/full/jcb.200602125/DC1).
Finally, the involvement of the GTPase Rho, which func-
tions as the key effector that directly binds and activates ROCK 
(Riento and Ridley, 2003), was investigated. Previous work es-
tablished a role for Endo180 in the activation of the other two 
Rho family GTPases, Cdc42 and Rac (but not Rho), during 
uPA-mediated “directional” migration (chemotaxis; Sturge 
et al., 2003). However, the Endo180-dependent signaling path-
ways that promote “random” cell migration were not examined. 
To investigate whether ROCK activation by Endo180 occurs 
through the Rho pathway, levels of active Rho were measured in 
lysates of MG63 cells treated with Endo180 siRNA. The results 
of these experiments confi  rm that Rho activation is a down-
stream target of Endo180 (Fig. 4 b). Further, the inability of 
ROCK inhibitor to block Rho activity (Fig. 4 b) confi  rms previ-
ous reports that ROCK lies downstream of Rho. Interestingly, 
Figure 3.  Tails produced by targeted inhibition of Endo180 or ROCK re-
sult from defective rear cell deadhesion and increased cell body movement. 
MG63 cells were left untreated or treated with siRNA oligonucleotides 
(control or Endo180) for 72 h before plating onto uncoated coverslips. 
Cells were allowed to adhere for 1 h before cellular dynamics were visual-
ized by time-lapse video microscopy (see Videos 1–3, available at http://
www.jcb.org/cgi/content/full/jcb.200602125/DC1). 1 μM ROCK in-
hibitor was added to untreated cells 30 min before image collection and 
was present during image collection. (a) Stills from representative time-
lapse videos taken at 0 h, 30 min, 1 h, and 4 h are shown. Arrows indi-
cate examples of the tails formed during the assay. Bar, 50 μm. (b) Cells 
from time-lapse videos were quantiﬁ  ed for their cell body movement. Data 
are mean cell body movement in μm/h ± SEM; >100 cells were analyzed 
in each of three separate experiments. *, P < 0.0001, compared with 
control levels.
Figure 4.  Endo180 activates the Rho–ROCK signaling pathway. (a and b) 
MG63 cells plated on uncoated tissue culture plastic were treated with 
control or Endo180 siRNA oligonucleotides for 72 h or untreated/treated 
with 0.3 μM ROCK inhibitor for 4 h. (a) Cell lysates were immunoblotted 
to detect phosphorylation of MLC2 at serine 19, total MLC2, MYPT1 phos-
phorylation at threonine 696, total MYPT1, phosphorylation of LIMK1/2 at 
threonine 508/threonine 505, and total LIMK1. (top) Representative immuno-
blots. (bottom) Phosphorylation levels of the indicated ROCK targets quanti-
ﬁ  ed by densitometry. Data are mean of three separate experiments ± SEM. 
*, P < 0.01, compared with control siRNA or untreated levels. (b) Active 
Rho was afﬁ  nity precipitated from cell lysates, and precipitates and cell ly-
sates were immunoblotted to detect active and total Rho levels, respectively. 
(top) A representative immunoblot. (bottom) Rho activation levels quanti-
ﬁ  ed by densitometry. Data are mean of ﬁ  ve separate experiments ± SEM. 
*, P < 0.00001, compared with control siRNA levels. (c) MG63 cells were 
left untreated or treated with TAT-C3 toxin for 16 h. The actin cytoskeleton 
was visualized by staining with Alexa 488 phalloidin (green), and cell nu-
clei were counterstained with TO-PRO-3 (blue). Images shown are repre-
sentative of two separate experiments. Bar, 25 μm.ENDO180 SPATIALLY REGULATES CELL CONTRACTILITY • STURGE ET AL. 341
the inhibition of Rho by TAT-C3 transferase in MG63 cells pro-
duced an unretracted tail phenotype similar to that observed 
in Endo180 siRNA– or ROCK inhibitor–treated cells (compare 
Fig. 4 c and Fig. 1 a). Collectively, these data suggest the exis-
tence of an Endo180–Rho–ROCK–MLC2 signaling pathway 
that is involved in rear cell retraction.
Spatial regulation of MLC2 phosphorylation 
in unretracted tails is associated with 
the accumulation of endosomal Endo180
Spatial regulation of MLC2 has been proposed to occur through 
localized signals that emanate from different upstream effectors 
(Totsukawa et al., 2004). It has also been hypothesized that en-
dosomes have the capacity to perpetuate and/or amplify intra-
cellular signaling pathways (Kermorgant et al., 2004; Polo 
et al., 2004; Le Roy and Wrana, 2005). Consequently, it was 
important to determine whether Endo180 could spatially local-
ize to activate Rho–ROCK–MLC2 during rear cell deadhesion 
and tail retraction.
First, live cells were stained at 4°C with Endo180 anti-
body to assess the cell surface distribution of this receptor. 
  Unlike integrins that cluster at the cell surface of unretracted 
tails after ROCK inhibition (Worthylake et al., 2001), no accu-
mulation or clustering of plasma membrane Endo180 at the un-
retracted tails was observed in ROCK inhibitor–treated cells 
(Fig. 5 a). Instead, the receptor remained uniformly distributed 
across the plasma membrane in punctate structures, consistent 
with previous reports that 10–30% of cellular Endo180 is local-
ized to the plasma membrane in clathrin-coated pits (Isacke et al., 
1990). In contrast, immunofl  uorescent staining and confocal 
microscopy of Endo180 in permeabilized ROCK inhibitor–
treated cells revealed a dramatic accumulation of Endo180 in the 
majority of unretracted tails (Fig. 5 b; 79 ± 4%; >50 cells scored 
in each of three separate experiments). High-magnifi  cation and 
multiple xz and yz confocal imaging of unretracted tails con-
fi  rmed that this accumulated Endo180 was localized to intracel-
lular endosomes (Fig. 5 b). In contrast, in cells treated with 
either ROCK inhibitor or Endo180 siRNA, ROCK itself did not 
accumulate/relocalize to rear cell adhesion sites and remained 
diffusely cytosolic (unpublished data). Importantly, a small 
number (4 ± 1%; >50 cells scored in each of three separate 
  experiments) of untreated migrating cells also displayed very 
strong localization of Endo180-containing endosomes to cell–
matrix adhesion sites at the termini of stress fi  bers or unretracted 
tails (Fig. 5 b, arrowhead). This confi  rms that accumulation of 
Endo180-containing endosomes occurs in normally migrating 
cells and suggests that the relatively small number of normal 
cells displaying localization of Endo180 to adhesion sites re-
fl  ects the highly dynamic nature of endosomal traffi  cking dur-
ing cell migration.
Second, the Endo180 endosomes were characterized to 
address two questions. Is the accumulation of Endo180 in the 
unretracted tails of ROCK inhibitor cells specifi  c to this endo-
cytic receptor, and does the accumulation of Endo180 refl  ect a 
change in endosomal traffi  cking caused by the inhibition of 
ROCK? For this purpose, the colocalization of Endo180 with 
transferrin receptor (a constitutively recycling receptor), early 
endosome antigen 1 (EEA1; a marker for sorting endosomes), 
and Rab11 (a marker for pericentriolar recycling endosomes; 
Zerial and McBride, 2001) was assessed. In untreated cells, 
Endo180 displayed near total colocalization with transferrin 
  receptor and partial colocalization with both EEA1 and Rab11 
(Fig. 6), demonstrating that Endo180, like the transferrin recep-
tor (Sonnichsen et al., 2000), is localized to both rapidly recy-
cling EEA1-positive sorting endosomes and slower recycling 
Rab11-positive pericentriolar endosomes. In ROCK inhibitor–
treated cells, both transferrin receptor and EEA1 strongly accu-
mulated with highest concentrations of these endosomal markers 
observed in the unretracted tails. A similar distribution of Rab11 
was not evident in ROCK inhibitor–treated cells. As in un-
treated cells, Rab11 was uniformly distributed throughout ROCK 
inhibitor–treated cells, with the highest concentrations accumu-
lated in pericentriolar recycling endosomes. The unretracted 
tails in ROCK inhibitor–treated cells were quantifi  ed by scoring 
for their accumulation of high concentrations of Endo180 to-
gether with high concentrations of transferrin receptor, EEA1, 
or Rab11. In this analysis, Endo180 displayed an almost total 
coaccumulation with transferrin receptor (98 ± 2%), a partial 
Figure 5.  Endosomes containing Endo180 localize at cell–matrix adhe-
sion sites and strongly accumulate in unretracted tails. MG63 cells were 
plated onto uncoated glass coverslips. (a) To label cell surface Endo180, 
cells were left untreated or treated for 4 h with 0.3 μM ROCK inhibitor and 
incubated at 4°C with anti-Endo180 mAb A5/158 before ﬁ  xation and ad-
dition of Alexa 555 anti-mouse Ig (red) and counterstaining of nuclei with 
TO-PRO-3 (blue). (b) Cells were left untreated or treated with 0.3 μM 
ROCK inhibitor for 4 h or TAT-C3 for 16 h. Cells were ﬁ  xed and stained 
with Alexa 488 phalloidin to visualize the actin cytoskeleton (green), anti-
Endo180 mAb A5/158 (red), and nuclei counterstained with TO-PRO-3 
(blue). Bar, 50 μm. Arrowhead indicates endosomes containing Endo180 
accumulating at stress ﬁ  ber termini in untreated cells. The far right image 
shows boxed area at higher (8×) magniﬁ   cation. z sections show that 
Endo180-positive endosomes strongly accumulate inside unretracted tails 
of ROCK inhibitor–treated cells.JCB • VOLUME 175 • NUMBER 2 • 2006  342
coaccumulation with EEA1 (24 ± 7%), and only minimal co-
accumulation with Rab11 (4 ± 1%; Fig. 6), indicating that it is 
the redistribution of receptor-positive endosomes, rather than the 
altered internalization/export of receptors, that accounts for the 
tail localization and that accumulation of endocytic receptors in 
unretracted tails is not exclusive to Endo180. Despite this lack 
of exclusivity, it is notable that transferrin receptor also strongly 
accumulated in the unretracted tails of Endo180 siRNA–treated 
cells (unpublished data), supporting previous experimental fi  nd-
ings (Fig. 1) that transferrin receptor has no functional role in 
the promotion of cell contractility during rear tail retraction. 
In contrast, further support for the mechanistic regulation of cell 
contractility by Endo180 was provided by the observation in 
untreated cells that Endo180-containing endosomes strongly 
accumulate at adhesion sites and unretracted tails that have a lo-
calized high level of MLC2 phosphorylation (Fig. 7).
Endo180 internalization is required for 
spatial adhesion assembly and disassembly 
and the generation of contractile signals
The ability of Endo180 to regulate the adhesion/deadhesion 
process and generate contractile signals could emanate from the 
plasma membrane or internalized endosomes. To address this, 
studies were undertaken using the Endo180(Ala
1468/Ala
1469) 
mutant, which is expressed at the cell surface but internaliza-
tion defective (Howard and Isacke, 2002; Wienke et al., 2003). 
It has previously been demonstrated that the expression of 
wild-type Endo180 promotes MCF7 cell migration, whereas 
Endo180(Ala
1468/Ala
1469) does not (Sturge et al., 2003). For these 
experiments, stable transfectants with equal protein-expression 
levels of wild-type Endo180 and Endo180(Ala
1468/Ala
1469) 
were generated (Fig. S5, available at http://www.jcb.org/cgi/
content/full/jcb.200602125/DC1). As expected from its promigra-
tory function, expression of wild-type Endo180 increased cell 
spreading and the assembly of new focal adhesions (Fig. 8 a). 
In addition, these transfected cells showed enhanced adhesion to 
a Matrigel substratum (Fig. 8 b), consistent with a previous report 
that cells from mice with a targeted deletion in Endo180 show a 
defect in adhesion to a variety of collagen substrata (Engelholm 
et al., 2003). The Endo180(Ala
1468/Ala
1469) mutant contains an 
intact collagen binding domain and, as expected, supported 
a level of adhesion to Matrigel similar to that of wild-type 
Endo180 (Fig. 8 b). However, Endo180(Ala
1468/Ala
1469) did not 
promote cell spreading and spatial assembly of new focal adhe-
sions (Fig. 8 a). Rather, both vector alone and Endo180(Ala
1468/
Ala
1469) transfected cells developed an elongated phenotype 
upon plating (Fig. 8 a), with tail structures that were reminis-
cent of those observed in Endo180 siRNA– or ROCK inhibitor–
treated cells (compare Figs. 1 a and 8 a). Moreover, in these 
cells, talin was seen to accumulate in the tail structures. These 
data indicate that an uncoupling of adhesion and deadhesion 
underlies the migration defect observed in cells expressing the 
internalization-defective Endo180(Ala
1468/Ala
1469) mutant and 
that although internalization of Endo180 is not necessary for the 
promotion of initial cell–matrix adhesions, it is required for the 
correct spatial formation and effi  cient turnover of cell–matrix 
adhesions during cell spreading and migration.
Next, several approaches were taken to confi  rm that Endo180 
internalization is required for the generation of contractile   signals. 
Figure 6.  Endo180 in unretracted tails colocalizes with transferrin recep-
tor and accumulates in early sorting but not recycling endosomes. MG63 
cells plated onto uncoated coverslips were left untreated or treated with 
0.3 μM ROCK inhibitor for 4 h, ﬁ  xed, and stained with anti-Endo180 mAb 
A5/158 (green) and antibodies against transferrin receptor (TfR), EEA1, 
or Rab11 as markers of different endosomal compartments (red). Nuclei 
were counterstained with TO-PRO-3 (blue). Images shown are representa-
tive of three separate experiments. Bar, 25 μm. Values represent the per-
centage of unretracted tails in ROCK inhibitor–treated cells that show 
coaccumulation of Endo180 with TfR, EEA1, or Rabl11. Data represents 
>50 cells counted in each of three separate experiments ± SEM.
Figure 7.  Endo180-positive endosomes directly localize at sites of cell–
matrix adhesion with increased contractile signals. MG63 cells plated onto 
uncoated coverslips were ﬁ  xed and stained with Alexa 488 phalloidin to 
visualize the actin cytoskeleton (green), anti-Endo180 mAb A5/158 (red), 
and anti–diphosphorylated MLC2 (blue). Two representative images are 
shown. Asterisks indicate regions shown in the right-hand images at higher 
(4×) magniﬁ  cation. Bar, 50 μm.ENDO180 SPATIALLY REGULATES CELL CONTRACTILITY • STURGE ET AL. 343
First, it was demonstrated that MLC2 phosphorylation gener-
ated by serum stimulation of starved cells was signifi  cantly 
  elevated in cells transfected with Endo180 compared with 
that generated by cells transfected with vector alone or 
Endo180(Ala
1468/Ala
1469) (Fig. 9 a and Fig. S5). Second, using a 
method that has been used to demonstrate the existence of intra-
cellular endosomal signaling events (Kermorgant et al., 2004), 
cells were stimulated with serum for 10 min and the extracellu-
lar stimulus was withdrawn. Upon serum withdrawal, elevated 
MLC2 phosphorylation levels persisted for at least 2 h in 
Endo180-expressing cells but rapidly returned to basal levels 
(within 10 min) in vector alone transfected cells (Fig. 9 b). 
  Finally, the recycling of endosomal components back to the 
plasma membrane was inhibited using primaquine (Woods 
et al., 2004) in serum-starved cells. As expected, primaquine 
  resulted in a dramatic decrease in the localization of Endo180 at 
the cell surface (Fig. 9 c) but did not affect total cellular levels 
of Endo180 (Fig. 9 d), indicating that Endo180 had been inter-
nalized but not recycled back to the plasma membrane. The 
  resultant fourfold increase in MLC2 phosphorylation in 
  primaquine-treated cells indicated that intracellular accumula-
tion of Endo180 was suffi  cient to stimulate a contractile re-
sponse that was blocked by the presence of ROCK inhibitor 
(Fig. 9 e). The observation that MLC2 phosphorylation levels 
remain unchanged in primaquine-treated vector alone trans-
fected cells (Fig. 9 e) provides independent evidence that 
other recycling receptors, such as transferrin receptor and β1 
  integrin (CD29), are not involved in the regulation of this sig-
naling event. The results of these experimental approaches 
 con fi  rm that the internalization of Endo180 into endosomes 
can generate and sustain ROCK-dependent intracellular 
 contractile  signals.
Endo180–ROCK signaling disrupts 
adherens junctions
Because Endo180 can promote localized ROCK–MLC2 signal-
ing during tail retraction, we further hypothesized that ectopic 
expression of this receptor in epithelial cells should be suffi  cient 
to promote disassembly of their adherens junctions, as ROCK-
based contractility can disrupt cell–cell adhesions (Sahai and 
Marshall, 2002). The expression of Endo180 in MCF7 cells re-
sulted in the loss of E-cadherin from cell–cell junctions, and 
this was reversed by treatment with ROCK inhibitor (Fig. 10, 
a and b). This effect was not specifi  c to E-cadherin, as a similar 
redistribution was also observed with immunofl  uorescent stain-
ing of the junctional component α-catenin (unpublished data). 
Moreover, the decreased stability of MCF7 cell–cell junctions 
in cells ectopically expressing Endo180 was reversed by 
Endo180 siRNA treatment (Fig. 10, c and d). These fi  ndings 
suggest that in addition to regulating the disassembly of cell–
matrix adhesions at the cell rear during cell migration, Endo180 
has the capacity to activate ROCK and generate contractile sig-
nals that promote the disassembly of adherens junctions at epi-
thelial cell–cell contacts.
Discussion
Our results point to a role for endosomes in the disassembly 
mechanism for cell–matrix and cell–cell adhesions. In particu-
lar, we have demonstrated that the endocytic localization of the 
Endo180 receptor activates mechanotransduction pathways that 
promote cell contractility and adhesion disassembly. A role for 
Endo180-containing endosomes in adhesion disassembly is 
complemented by a report that identifi  ed dynamin as a down-
stream target for microtubule-induced focal adhesion disassem-
bly in fi  broblasts (Ezratty et al., 2005). Dynamin provides a 
ubiquitous molecular mechanism for driving endocytosis via its 
ability to recruit actin monomers to the neck of clathrin-coated 
pits, where their polymerization is required to force endosome 
internalization and propulsion through the dense cytocortex into 
the cytosol (Orth and McNiven, 2003).
Because the expression of Endo180 is predominantly re-
stricted to fi  broblasts and other highly motile cells, including a 
range of highly invasive cancer cell types (Behrendt et al., 2000; 
Figure 8.  Internalization of Endo180 into endosomes promotes spatial 
adhesion turnover. (a) Vector alone, Endo180, and Endo180(Ala
1468/
Ala
1469) transfected MCF7 cells were plated onto Matrigel-coated cover-
slips for 4 h, ﬁ  xed, and stained with Alexa 488 phalloidin to visualize the 
actin cytoskeleton (green). Anti-talin was used as a marker of focal adhe-
sion (red), and nuclei were counterstained with TO-PRO-3 (blue). Images 
shown are representative of three separate experiments. Bar, 50 μm. 
(b) Transfected MCF7 cells were plated onto Matrigel-coated tissue cul-
ture plastic for 1 h, and the percentage of adherent cells relative to vector 
alone transfected MCF7 is shown as mean of three separate experi-
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East and Isacke, 2002), this receptor could represent a highly 
specifi  c endocytic component involved in focal adhesion disas-
sembly during cell migration. In this respect, we would predict 
that the endocytosis-driven system of tail retraction promoted 
by Endo180–Rho–ROCK–MLC2 mechanotransduction acts 
downstream of the microtubule-mediated activation of dynamin. 
This hierarchy of molecular events gains additional support 
from earlier work that placed Rho–ROCK signaling down-
stream of microtubule-mediated adhesion disassembly during 
monocyte tail retraction (Worthylake et al., 2001). Moreover, it 
is notable in the experiments described here that the localization 
of Endo180-containing endosomes to the cell rear adhesion 
sites in cells treated with ROCK inhibitor is reminiscent of the 
mature integrin adhesions that accumulate in the unretracted 
tails of Rho-inhibited monocytes (Worthylake et al., 2001). It is 
well established that Endo180 functions as a collagen receptor, 
mediating ligand uptake for delivery to intracellular degradative 
organelles (Engelholm et al., 2003; Wienke et al., 2003; Curino 
et al., 2005), but we fi  nd here that binding of collagen is mecha-
nistically independent of the ability of Endo180 to promote cell 
migration. This suggests that Endo180 has a constitutive func-
tion in promoting cell migration that is unrelated to the binding 
of exogenously added collagen. Indeed, the ability of Endo180 
to couple with the signaling network that drives cell migration 
was previously implied by its involvement in the activation of 
Cdc42 and Rac by uPA and effi  cient sensing of a uPA chemo-
tactic gradient (Sturge et al., 2003). The key questions that 
now need to be addressed are whether Endo180 signals to Rho 
GTPases via individual or multiple guanidine nucleotide exchange 
factors and/or other membrane-associated components local-
ized in endosomes and whether the endogenous collagens pro-
duced by the Endo180-expressing cells may modulate receptor 
activity. It certainly remains a distinct possibility that Endo180 
promotes uptake of focal adhesion components bound to extra-
cellular collagen during collagen internalization and that this 
could impact cell migration.
A key fi  nding of the studies described here is that the gen-
eration of contractile signals by Endo180 was not elicited from 
the plasma membrane but rather from Endo180 localized in 
intracellular endosomes. Further, the differential colocalization 
of other endosomal markers with Endo180 in ROCK inhibitor–
treated cells indicated that it is the Endo180-positive sorting en-
dosomes that preferentially accumulate at the rear cell adhesion 
sites. Notably, in these tail structures, the extensive colocaliza-
tion of Endo180 and transferrin receptor is retained. Together 
with the data showing that there is no accumulation of Endo180 
on the plasma membrane of unretracted tails, this suggests that 
the accumulation of endosomal Endo180 in the tails results from 
Figure 9.  Internalization of Endo180 into 
  endosomes promotes the generation of con-
tractile signals. Cells were plated onto 
Matrigel-coated tissue culture plastic. (a) 
  Serum-starved vector alone, Endo180, and 
Endo180(Ala
1468/Ala
1469) transfected MCF7 
cells were treated with or without 10% FCS for 
10 min. Lysates were resolved by SDS-PAGE 
and diphospho-MLC2 and total MLC2 detected 
by immunoblotting. (bottom) Representative im-
munoblots from 10 separate experiments. (top) 
MLC2 phosphorylation levels quantiﬁ  ed  by 
densitometry. Data are mean ± SEM. n = 10. 
*, P < 0.001, compared with FCS-stimulated 
vector alone and Endo180(Ala
1468/Ala
1469) 
transfected MCF7 cells. (b) Serum-starved vec-
tor alone and Endo180 transfected MCF7 cells 
were treated with or without 10% FCS for 10 
min, washed twice in PBS, and incubated in 
serum-free medium for 10 min, 30 min, 1 h, or 
2 h. Cells were lysed, and diphospho-MLC2 
and total MLC2 were detected by immunoblot-
ting. (top) Representative immunoblots from 
two separate experiments. (bottom) MLC2 
phosphorylation levels quantiﬁ  ed by densitom-
etry. Data are mean ± SEM. n = 2. (c and d) 
Serum-starved vector alone or Endo180 trans-
fected MCF7 cells were either untreated or 
treated with primaquine for 30 min. (c) The cell 
surface levels of Endo180, transferrin receptor 
(TfR), and β1 integrin (CD29) was assessed by 
ﬂ  ow cytometry. Data shown are mean relative 
ﬂ   uorescent intensity normalized against iso-
type-matched IgG binding. (d) Cell lysates 
were resolved by SDS-PAGE, and Endo180 
was detected by immunoblotting. (e) Serum-
starved vector alone and Endo180 transfected 
MCF7 cells were untreated or treated with pri-
maquine for 30 min. Where indicated, cells 
were incubated with 0.3 μM ROCK inhibitor for 1 h before primaquine stimulation. Lysates were resolved by SDS-PAGE, and diphospho-MLC2 and total 
MLC2 were detected by immunoblotting. (bottom) Representative immunoblots from four separate experiments. (top) MLC2 phosphorylation levels quanti-
ﬁ  ed by densitometry. Data are mean ± SEM. *, P < 0.05, compared to all other treatments. n = 4.ENDO180 SPATIALLY REGULATES CELL CONTRACTILITY • STURGE ET AL. 345
a redistribution of Endo180/transferrin receptor–positive endo-
somes rather than from altered internalization/export kinetics of 
Endo180. However, we cannot rule out the possibility that export 
of Endo180 and transferrin receptor from sorting endosomes in 
the tails may also be reduced by ROCK inhibition. The colocal-
ization of Endo180 and transferrin receptor in ROCK inhibitor–
treated cells demonstrates that the accumulation of endocytic 
receptors is not exclusive to Endo180. However, the transferrin 
receptor also showed a strong accumulation in the unretracted 
tails of Endo180 siRNA–treated cells (unpublished data), and 
down-regulation of transferrin receptor by siRNA treatment had 
no effect on tail retraction or phosphorylation of MLC2. More-
over, primaquine treatment of Endo180-negative cells resulted 
in the intracellular accumulation of transferrin receptor and β1 
integrin but did not enhance MLC2 phosphorylation. As a con-
sequence, we conclude that, at least among the endocytic re-
ceptors examined, Endo180 has an exclusive functional role in 
promoting cell contractility during rear tail retraction. Finally, 
the observation that ROCK itself did not accumulate/relocalize 
to rear cell adhesion sites and remained diffusely cytosolic in 
either ROCK inhibitor– or Endo180 siRNA–treated cells indi-
cates that Endo180 localization at these sites could be the rate-
limiting step in the spatial activation of ROCK and has led us to 
propose that the localization of Endo180-containing endosomes 
results in the spatial activation of Rho–ROCK–MLC2 to pro-
mote adhesion disassembly.
In addition to regulating adhesion of cells to a substratum, 
ROCK can regulate the integrity of cell–cell adhesion com-
plexes (Riento and Ridley, 2003). Although there are confl  icting 
reports in the literature as to whether ROCK activity promotes 
an increased (Walsh et al., 2001; Eisen et al., 2004; Shewan 
et al., 2005) or decreased (Vaezi et al., 2002; Wojciak-Stothard 
and Ridley, 2002) integrity of intercellular junctions and perme-
ability of cell monolayers, activation of ROCK has been shown 
to result in the disruption of E-cadherin–containing adherens 
junctions and the redistribution of junctional components in ep-
ithelial cells in culture (Sahai and Marshall, 2002; Croft et al., 
2004). The demonstration here that ectopic expression of 
Endo180 results in a redistribution of E-cadherin in epithelial 
monolayers and that this redistribution can be reversed by treat-
ment with ROCK inhibitor provides further support for a role of 
Endo180 as an upstream regulator of ROCK. These data addi-
tionally suggest that aberrant expression of Endo180 in epithe-
lial cells may promote the acquisition of a more mesenchymal 
migratory phenotype, and in this respect it is of interest that the 
noninvasive MCF7 epithelial cell line is Endo180-negative, 
whereas the more aggressive BE and MDA-MB-231 tumor 
lines are Endo180-positive.
These studies, combined with previous work, have dem-
onstrated that Endo180 has a dual function, acting both as a 
regulator of Rho–ROCK–MLC2 signaling and as a collagen in-
ternalization receptor. To date, the most striking in vivo pheno-
type resulting from manipulating Endo180 expression comes 
from crossing mice with a mammary tumor–predisposing trans-
gene to mice with a targeted deletion in Endo180. These mice 
develop tumors at the same rate as those expressing wild-type 
Endo180 but show an increased collagen deposition in the 
  tumor-associated stroma and a decreased tumor burden (Curino 
et al., 2005). Given the data presented here, we propose that this 
phenotype arises not only from the inability of Endo180-null fi  -
broblasts to remodel the collagen-rich extracellular matrix but 
also because such cells will also have a mechanotransduction 
defect that will impair their motility within the tumor. Given 
that these stromal cells are major collagen producers, this im-
paired motility will contribute to the aberrant accumulation of 
extracellular collagen. Certainly it will be of interest to deter-
mine whether Endo180 plays a similar role in other patho-
logical scenarios where altered fi  broblast activity and matrix 
turnover are associated with disease progression.
Materials and methods
Antibodies and cells
Anti-Endo180 mAb A5/158 has been previously described (Sheikh et al., 
2000). B3/25 anti–transferrin receptor mAb was a gift from C. Hopkins 
(Imperial College London, London, UK). Mouse anti–human LDLR was 
  obtained from Fitzgerald. Mouse anti–human uPAR was obtained from 
American Diagnostica, Inc. Rabbit anti–human monophospho-MLC2 
(Ser19) and diphospho-MLC2 (Thr18/Ser19), LIMK1, and phospho-LIMK1 
(Thr508)/LIMK2 (Thr505) were obtained from Cell Signaling. Mouse anti–
human MLC (clone MY21), MLCK, talin, and γ-tubulin were obtained from 
Figure 10.  Endo180 disrupts cell–cell adhesions through activation of 
ROCK-based contractility. Cells were plated onto Matrigel-coated tissue 
culture plastic. (a) Vector alone or Endo180 transfected MCF7 cells un-
treated or treated with 0.3 μM ROCK inhibitor for 24 h were ﬁ  xed and 
stained for E-cadherin (red), and nuclei were counterstained with TO-PRO-3 
(blue). Images shown are representative of three separate experiments. 
Bar, 25 μm. (b) E-cadherin junctional staining of cells, shown in panel a, 
were scored as weak, intermediate, or strong. 7–10 ﬁ  elds of view were 
scored from each of three separate experiments. Data are mean percent-
age of cells in each category ± SEM. *, P < 0.05, compared with vector 
alone transfected cells. (c) Endo180 transfected MCF7 cells were treated 
with control or Endo180 siRNA oligonucleotides, ﬁ  xed, and stained to vi-
sualize E-cadherin (red), Endo180 (green), and cell nuclei (blue). Images 
shown are representative of three separate experiments. Bar, 25 μm. 
(d) E-cadherin junctional staining was scored as described for panel c. 7–10 
ﬁ  elds of view from each of three separate experiments were scored. Data 
are the mean percentage of cells in each category ± SEM. *, P < 0.05, 
compared with control siRNA transfected cells.JCB • VOLUME 175 • NUMBER 2 • 2006  346
Sigma-Aldrich. Mouse anti–human MYPT1, ROCK1, ROCK2, ZIP kinase, 
EEA1, and Rab11 were obtained from BD Biosciences. Rabbit anti–human 
phospho-MYPT1 (Thr696) was obtained from Upstate Biotechnology. Rabbit 
anti–human MRCKα and MRCKβ were a gift from S. Wilkinson (Institute 
of Cancer Research, London, UK; Wilkinson et al., 2005). Mouse anti–
  human CD29 was obtained from Serotec. Mouse anti–human E-cadherin 
(clone HECD-1) was obtained from Abcam; secondary antibodies Alexa 
Fluor 488/555 anti-rabbit Ig and Alexa Fluor 488/555 anti-mouse Ig, 
  Alexa Fluor 488/555/633 phalloidin, and TO-PRO-3 were obtained from 
Invitrogen. HRP anti-mouse Ig was obtained from Jackson ImmunoResearch 
Laboratories, and HRP anti-rabbit Ig was obtained from Santa Cruz Bio-
technology, Inc. E-cadherin antibody was labeled using Zenon Alexa Fluor 
555 mouse IgG1 labeling kit (Invitrogen). For some experiments, Endo180 
directly conjugated to Alexa Fluor 488 (Invitrogen) was used. MG63, 
MDA-MB-231, HT1080, and BE cells were maintained in DME + 10% 
FCS. MCF7 cells transfected with vector alone, wild-type Endo180, and 
Endo180(Ala
1468/Ala
1469) were cultured as previously described (Wienke 
et al., 2003).
Immunostaining and confocal imaging
Immunostaining and cell surface labeling of Endo180 were performed as 
described previously (Howard and Isacke, 2002; Sturge et al., 2003). For 
confocal imaging, cells were ﬁ  xed, stained, and mounted in Vectashield 
H-1000 (Vector Laboratories) at room temperature. Images were captured 
at room temperature with a confocal microscope (TCS SP2; Leica) and 
Confocal Software (Leica) using 63× (1.40 NA, oil; Leica) or 40× (1.25 
NA, oil; Leica) lenses and Immersol 518F oil (Carl Zeiss MicroImaging, 
Inc.). Images were imported in to Photoshop 8.0 (Adobe) for processing.
Immunoblotting and Rho activity assays
Immunoblotting was performed as described previously (Sturge et al., 2003). 
Rho activation assay kit was purchased from Upstate Biotechnology, and as-
says were performed according the manufacturer’s guidelines. The cell per-
meable TAT-C3 transferase toxin was a gift from G. Mavria (The Institute of 
Cancer Research, London, UK). Quantiﬁ  cation of phosphorylation levels and 
Rho activation were measured using ImageJ densitometric software. Data is 
adjusted for loading and normalized to 100% for control levels ± SEM.
Cell treatments
Endo180, reversed Endo180 (control siRNA), and uPAR single siRNA oli-
gonucleotides were as described previously (Sturge et al., 2003; Vial 
et al., 2003). Transferrin receptor, LDLR, and Endo180 were targeted using 
SMARTpool siRNA oligonucleotides (Dharmacon). siRNA oligonucleotides 
(20 nmol/ml) were transfected into cells seeded on coverslips or culture 
dishes (30–50% conﬂ   uent) with 100 μM Oligofectamine (Invitrogen) in 
Opti-MEM reduced-serum medium (Invitrogen). Knock down of targeted re-
ceptors was assessed by ﬂ  ow cytometry as previously described (Sturge 
et al., 2003; Wienke et al., 2003). Optimal knockdown was obtained 72 h 
after transfection. The highly speciﬁ  c ROCK inhibitor (S)-(+)-2-Methyl-1-[(4-
methyl-5-isoquinolinyl)sulfonyl]homopiperazine, 2HCl (Calbiochem) was 
diluted in culture media from a stock solution of 10 mM in sterile water. 
TAT-C3 transferase toxin was diluted in culture media from a stock solution 
of 7.2 μM and used at a ﬁ  nal concentration of 1 μM. To inhibit endocytic 
recycling, MCF7 cells were starved for 48 h in DME before incubation with 
0.6 μM primaquine (Sigma-Aldrich).
Video microscopy
MG63 cells were left untreated or treated with siRNA oligonucleotides for 
72 h. Cells were seeded on coverslips and allowed to adhere for 1 h. The 
coverslips were then placed on to counting chambers (Hawksley Technol-
ogy) and sealed with wax as previously described (Sturge et al., 2003). 
siRNA-treated cells were assayed in fresh growth medium, and ROCK 
  inhibitor–treated cells were assayed in fresh growth medium containing 
1 μM ROCK inhibitor, which was added to cells 30 min before the start of 
image collection. Images of cells were digitally recorded at a time-lapse in-
terval of 1 min for 4 h using an microscope (IX70; Olympus) ﬁ  tted with hu-
midiﬁ  ed 37°C incubation chamber, a 20× lens (0.4 NA, dry; Olympus), 
and Simple PCI acquisition software (Digital Pixel). Speed of cell body 
movement (mean ± SEM; n > 100 cells) was calculated as previously de-
scribed for mean cell migratory speed (Sturge et al., 2003) using Motion 
Analysis software (Kinetic Imaging Ltd) and Mathematica software 
(Wolfram Research Ltd).
Flow cytometry
Flow cytometry was performed as previously described (Wienke et al., 
2003). Data is presented as relative ﬂ  uorescent intensity (median ﬂ  uores-
cent intensity of antibody binding/median ﬂ  uorescent intensity of isotype-
matched control IgG binding) in which the isotype-matched control IgG 
binding is set at zero.
Cell adhesion assay
To measure adhesion, 10
3 Calcein AM–labeled cells were added to each 
well of a Matrigel-coated 96-well plate in growth medium. Cells were left 
for 1 h at 37°C and washed two times, and adherent cells were counted 
using a ﬂ  uorescence plate reader.
Online supplemental material
Fig. S1 shows a dose-dependent inhibition of MLC2 by ROCK inhibitor, 
ﬂ  ow cytometric analysis of receptor levels after siRNA treatment, and that 
the single Endo180 siRNA oligonucleotides and Endo180 SMARTpool 
oligonucleotides have similar effects on Endo180 knockdown and MLC2 
phosphorylation. Fig. S2 shows that treatment of MDA-MB-231 breast can-
cer cells with Endo180 siRNA oligonucleotides results in a tail-retraction 
defect similar to that seen in MG63 cells, in BE cells there is efﬁ  cient knock 
down of both Endo180 and uPAR after treatment with their respective siRNA 
oligonucleotides, and knock down of Endo180, but not uPAR, in BE cells 
results in a reduction of MLC2 phosphorylation. Fig. S3 shows that MCF7 
cells expressing Endo180 plated onto either Matrigel, collagen IV, or ﬁ  bro-
nectin show enhanced migration compared with vector alone transfected 
cells. Fig. S4 shows that treatment of MG63 cells with Endo180 siRNA 
oligonucleotides does not affect the expression levels of six MLC regulatory 
kinases. Fig. S5 shows expression levels of Endo180 and Endo180(Ala
1468/
Ala
1469) transfected into MCF7 cells. Videos 1–3 show time-lapse micros-
copy of control siRNA–, Endo180 siRNA–, and ROCK inhibitor–treated 
MG63 cells, respectively. Online supplemental material is available at 
http://www.jcb.org/cgi/content/full/jcb.200602125/DC1.
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